4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)oxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)oxazole
• 英文别名: 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl)-2-(2-methyl-1-imidazolyl)oxazole；4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methylimidazol-1-yl)-1,3-oxazole
• 化学式: C₂₃H₂₂ClN₃O₃
• 分子量: 423.899
• InChiKey: YMOSKPJTKUNTFI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  62.3
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propionic acid 在 lithium aluminium tetrahydride 、 三丁基膦 、 potassium carbonate 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 22.0h， 生成 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)oxazole
  参考文献：
  名称：

  Synthesis and Biological Activity of Novel 5-(.OMEGA.-Aryloxyalkyl)oxazole Derivatives as Brain-Derived Neurotrophic Factor Inducers

  摘要：

  一系列新颖的5-(ω-芳氧基烷基)噁唑衍生物被制备出来，并在人神经母细胞瘤（SK-N-SH）细胞中评估了它们对脑源性神经营养因子（BDNF）产生的影响。合成过程通过构建噁唑环作为关键反应来完成。大部分5-(ω-芳氧基烷基)噁唑衍生物显著增加了SK-N-SH细胞中的BDNF产量。其中一种非常有前景的化合物，即4-(4-氯苯基)-2-(2-甲基-1H-咪唑-1-基)-5-[3-(2-甲氧基苯氧基)丙基]-1,3-噁唑，显示了强大的活性（EC50=7.9微摩尔），并且伴随脑源性神经营养因子水平在链脲佐菌素（STZ）诱导的糖尿病大鼠坐骨神经中的恢复，改善了运动神经传导速度和尾部拍打反应。

  DOI：

  10.1248/cpb.51.565

文献信息

• Fused ring compound
  申请人：Tawaraishi Taisuke

  公开号：US20080194617A1

  公开（公告）日：2008-08-14

  The present invention provides an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The present invention relates an agent for the prophylaxis or treatment of diabetes, which comprises a compound represented by wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof.

  本发明提供了一种用于预防或治疗糖尿病的药剂，具有优越的降血糖作用，并且与较少的副作用（如体重增加等）相关。本发明涉及一种用于预防或治疗糖尿病的药剂，包括由下式表示的化合物：其中每个符号如描述中所定义，或其盐或前药。
• Oxazole derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06177452B1

  公开（公告）日：2001-01-23

  A novel compound of the formula: wherein R1 is a halogen atom, an optionally substituted heterocyclic, hydroxy, thiol or amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, or an optionally esterified or amidated carboxy group; B is an optionally substituted aromatic group; Y is a divalent aliphatic hydrocarbon group, or a salt thereof, which have an excellent insulin secertion-promoting and blood sugar-depressing effect, and useful in agents for diabetes.

  一种新的化合物，其化学式如下：其中R1是卤素原子、可选择取代的杂环、羟基、硫醇或氨基团；A是可选择取代的酰基团、可选择取代的杂环基团、可选择取代的羟基团，或可选择酯化或酰胺化的羧基团；B是可选择取代的芳香基团；Y是二价脂肪烃基，或其盐，具有优秀的促进胰岛素分泌和降低血糖的作用，在糖尿病药物中有用。
• Vdac regulator
  申请人：Sugiyama Yasuo

  公开号：US20050234116A1

  公开（公告）日：2005-10-20

  The present invention provides a VDAC regulator comprising a compound represented by the formula (I): wherein R 1 is a halogen atom, an optionally substituted heterocyclic group, an optionally substituted hydroxy group, an optionally substituted thiol group or an optionally substituted amino group; A is an optionally substituted acyl group, an optionally substituted heterocyclic group, an optionally substituted hydroxy group or an optionally esterified or amidated carboxyl group; B is an optionally substituted aromatic group; X is an oxygen atom, a sulfur atom or an optionally substituted nitrogen atom; and Y is a divalent hydrocarbon group or heterocyclic group, a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of Down's syndrome and the like, and the like.

  本发明提供了一种VDAC调节剂，其包含由式（I）表示的化合物：其中，R1是卤素原子、可选取代的杂环基、可选取代的羟基、可选取代的硫醇基或可选取代的氨基；A是可选取代的酰基、可选取代的杂环基、可选取代的羟基或可选酯化或酰胺化的羧基；B是可选取代的芳香基；X是氧原子、硫原子或可选取代的氮原子；Y是二价的烃基或杂环基、其盐或前药，该化合物有用作预防或治疗唐氏综合症等疾病的药物。
• Neurotrophin production/secretion promoting agent
  申请人：Momose Yu

  公开号：US20080269219A1

  公开（公告）日：2008-10-30

  A neurotrophin production/secretion promoting agent which comprises an azole derivative of the formula: wherein R 1 represents a halogen atom, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, a thiol group which may optionally be substituted, or an amino group which may optionally be substituted; A represents an acyl group which may optionally be substituted, a heterocyclic group which may optionally be substituted, a hydroxy group which may optionally be substituted, or a carboxyl group which may optionally be esterified or amidated; B represents an aromatic group which may optionally be substituted; X represents oxygen atom, sulfur atom, or nitrogen atom which may optionally be substituted; and Y represents a divalent hydrocarbon group or heterocyclic group, or a salt thereof; which is useful as an agent for preventing or treating neuropathy.

  一种神经营养因子产生/分泌促进剂，包括式子如下的唑烷衍生物：其中，R1代表卤素原子、可能被取代的杂环基团、可能被取代的羟基、可能被取代的硫基或可能被取代的氨基；A代表可能被取代的酰基、可能被取代的杂环基团、可能被取代的羟基或可能被酯化或酰胺化的羧基；B代表可能被取代的芳香基团；X代表可能被取代的氧原子、硫原子或氮原子；Y代表双价烃基或杂环基团或其盐；该剂可用作预防或治疗神经病变的药剂。
• FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA
  申请人：Tawaraishi Taisuke

  公开号：US20110009384A1

  公开（公告）日：2011-01-13

  The present invention provides an agent for the prophylaxis or treatment of diabetes, which has a superior hypoglycemic action, and is associated with a fewer side effects such as body weight gain and the like. The resent invention relates an agent for the prophylaxis or treatment of diabetes, which comprises a compound represented by wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof.

  本发明提供了一种用于预防或治疗糖尿病的药剂，具有优越的降血糖作用，且与体重增加等副作用较少相关。本发明涉及一种用于预防或治疗糖尿病的药剂，包括下式所示的化合物：其中每个符号如说明书中所定义，或其盐或前药。